Results 71 to 80 of about 5,633 (190)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019 Background Uric acid (UA) is a plasmatic antioxidant that has possible effects on blood pressure. The effects of UA on endothelial function are unclear. We hypothesize that endothelial function is not impaired unless significant UA depletion is achieved ...
Benjamin De Becker +9 more
doaj +1 more source
Recent Advances in Intramolecular C─N Bond Formation for Pyrrolidine Synthesis
ChemistryOpen, Volume 15, Issue 6, June 2026.This review highlights synthetic advances (2013–2025) in intramolecular C─N bond formation for constructing the pharmaceutically relevant pyrrolidine core. The review is organized into five methodological clusters: 1) intramolecular alkene/alkyne amination; 2) tandem annulations, which involve C─N bond formation as the key step; 3) nucleophilic ...
Rasma Kroņkalne, Māris Turks
wiley +1 more source
Management of hyperuricemia in gout: focus on febuxostat
, 2010 Mattheus K Reinders1, Tim L Th A Jansen21Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands; 2Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, The NetherlandsAbstract: Gout is the most common inflammatory arthritis in an ...
Tim L Th A Jansen, Mattheus K Reinders
core
Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
, 2019 Background. Febuxostat is approved in the United States for the management of hyperuricemia in patients with gout. In November 2017 the FDA released a warning alert on a possible link between febuxostat and cardiovascular disease (CVD) reported in a ...
Cuenca, John A +5 more
core +1 more source
Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 189-206, June 2026.MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang +5 more
wiley +1 more source
Desensitization to febuxostat: report of two cases.
, 2015 Febuxostat has been recently introduced in the market as an alternative urate-lowering drug. Its allergenic profile has not been fully outlined and the clinical management of hypersensitivity reactions is not standardized.
Tosoni C. +6 more
core +1 more source
Benzofuran‐Based Uricosuric Agents: History, Roles, and Challenges
ChemistrySelect, Volume 11, Issue 24, 25 June 2026.Benzofuran‐based uricosuric agents represent a privileged medicinal chemistry scaffold for gout therapy. Structural optimization of benzbromarone‐related derivatives has improved hURAT1 inhibitory potency, metabolic stability, and urate‐lowering efficacy, while reducing hepatotoxic liability.
Raed M. Al‐Zoubi +7 more
wiley +1 more source
Febuxostat in the management of hyperuricemia and chronic gout: a review
, 2008 Miao Hu, Brian TomlinsonDivision of Clinical Pharmacology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, ChinaAbstract: Febuxostat is a novel, potent, non ...
Brian Tomlinson, Miao Hu
core
Febuxostat for the treatment of hyperuricaemia in gout
, 2018 Introduction: Febuxostat is a potent non-purine selective xanthine oxidase inhibitor approved by the FDA in 2009 for management of hyperuricemia in people with gout.Areas covered: The authors summarize the pre-clinical studies and pivotal randomized ...
Dalbeth, Nicola +2 more
core +1 more source